In conclusion, we certified the application of TLR7 agonists and the MAP structure in the design of gastric cancer vaccines, with T7 − MB providing benefits to tumor-bearing mice via CTLs and ADCC-mediating antibodies recognizing MG7-Ag. Here, TLR7 is linked to neoplasm.